Phase III trial results due for new use for Erbitux

03/19/2007 |

ImClone Systems and partner Bristol-Myers Squibb expect results in the next few weeks on whether their cancer drug shows positive Phase III trial results for treating pancreatic cancer. One analyst said the drug could have an upside in peak sales of $100 million to $250 million if the results are positive.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC